Skip to content

Inspiratory Muscle Therapy in Subjects With Fontan Circulations

A Pilot Study of Inspiratory Muscle Function and the Effects of Inspiratory Muscle Training in Subjects With Fontan Physiology

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03339466
Enrollment
7
Registered
2017-11-13
Start date
2016-01-29
Completion date
2017-08-31
Last updated
2024-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Single-ventricle

Brief summary

Individuals who have undergone the Fontan procedure are uniquely dependent upon respiratory mechanics to support pulmonary blood flow (PBF). The investigators hypothesized that enhanced respiratory muscle function via inspiratory muscle training (IMT) would improve performance on cardiopulmonary exercise stress testing (CPET).

Detailed description

Adult Fontan subjects were recruited from 2 academic medical centers. Following characterization of pulmonary function and functional class, CPET was performed using incremental and constant work rate protocols. Subjects performed 6-8 weeks of IMT using a handheld inspiratory loading device (Threshold®, Philips); both exercise tests were then repeated. Patient-centered outcome data were collected before and after IMT (RAND-36 assessment and New York Heart Association (NYHA) functional class).

Interventions

DEVICEInspiratory muscle therapy

6 weeks of inspiratory muscle therapy

Sponsors

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

Single ventricle physiology status post Fontan palliation

Exclusion criteria

* The presence of a sub-pulmonary ventricle * Pregnancy or any contraindication to stress testing (e.g., uncontrolled symptomatic arrhythmia, severe systemic ventricular outflow tract obstruction or uncontrolled symptomatic heart failure). * Height less than 4'11 due to limitations of the cycle ergometer.

Design outcomes

Primary

MeasureTime frameDescription
Exercise parameters6-8 weeksPeak VO2 and endurance time are the primary outcome measures

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026